Annals of the rheumatic diseases
POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES.
POS0864 ACHIEVEMENT OF REMISSION DEFINED BY ABSENCE OF OBJECTIVE SIGNS OF INFLAMMATION VERSUS ASDAS INACTIVE DISEASE IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES.
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION.
POS0773 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS.
POS0118 ASAS RECOMMENDATIONS ON REPORTING OUTCOMES OF CORE OUTCOME SET INSTRUMENTS IN AXIAL SPONDYLOARTHRITIS CLINICAL TRIALS.
Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
Satisfaction with telemedicine versus in-person visits in rheumatology: a noninferiority randomised controlled trial.
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.
1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis.
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
